NAD+ costs and commitments
NAD+ injection costs: look beyond the monthly headline.
In our current provider set, Pallas publishes $597.00 per twelve-week term and Luvo lists $199.00 for a four-week entry term. AgelessRx advertises $79.00 for the first month, but requires a three-month plan billed in full. Those are different commitments, not three directly comparable monthly payments. Supplied quantities, some fees and several renewal schedules remain unverified. This guide shows what is published, what can be calculated and why we cannot name a cheapest complete treatment plan from these headline prices alone.
4 sourced injection plans · USD · Alphabetical provider order, not a clinical ranking
| Provider / product | Advertised rate | Initial plan payment | Renewal evidence |
|---|---|---|---|
| AgelessRxNAD+ Injection Rx | $79.00first month; prepaid plan required | Not verified3-month plan billed in full | Published $149/mo after introductory first month; actual charge schedule must be checked at enrollment |
| EmbodyCompounded NAD+ Injections | $99.00per advertised month; promotional offer | Not verifiedCheckout period not verified | Page promises fixed $99/month pricing; checkout charge cycle and contract renewal terms still unverified |
| Luvo HealthNAD+ Injection | $27.00per week headline; annual term | $199.004-week term | Subscription renews; actual timing and renewal price disclosed at enrollment/account |
| Pallas HealthNAD+ injection | $199.00advertised monthly average | $597.0012-week term | $597.00Every 84 days |
Initial plan payment is the published treatment-term amount, not necessarily a charge at intake. Required extra fees and exact supplied quantities are not fully verified. No row establishes an equivalent dose, duration or result.
What is the cheapest NAD+ injection plan?
Among the entries with a published initial treatment-term amount in this audit, Luvo's $199.00 four-week option requires less initial plan spending than Pallas's $597.00 twelve-week term. It also covers a shorter period. That comparison does not account for unverified fees or establish equivalent medication quantities.
AgelessRx's first-month price and Embody's monthly headline cannot be sorted against a complete prepaid bill as if each were the same purchase. We do not fill the missing checkout totals with a calculation the source does not establish.
Why is the amount charged different from the advertised price?
A payment frequency is not an average.
Pallas's $199.00 monthly average is paired with a $597.00 charge every twelve weeks. Twelve weeks is 84 days, not three calendar months. A renewal can therefore fall inside a 90-day budgeting window.
Pallas NAD+ payment sourceA short price can hide a long commitment.
Luvo's $27.00 weekly headline belongs to its longest term, not a pay-every-week contract. Its shortest published term is four weeks. AgelessRx's first-month offer has a three-month prepayment condition.
Luvo term pricingAgelessRx NAD+ offerWhat would I pay across the first 90 days?
Assuming the first Pallas treatment-term payment occurs on September 15, 2026 and enrollment continues, the published schedule produces two plan payments inside a 90-day window: $597.00 initially and $597.00 at day 84. Known plan charges total $1,194.00. This is not a complete all-in quote because required additional fees and the effect of any credited intake deposit have not been fully verified.
Pallas published schedule · illustration only
Continued enrollment assumed. Window ends before 2026-12-14. Product source; deposit and cancellation terms.
For other listed plans, an unknown first bill or renewal schedule prevents a complete 90-day calculation. Open the payment explorer to change the start date and inspect known charges without inventing the rest.
What additional costs should I confirm?
Ask for the final written quote covering the clinical assessment, medication, supplies, shipping, required laboratory tests, follow-up and any membership charge. An inclusion listed on a general platform page may not apply to every product. “Not verified” in our table means the source did not establish the amount; it does not mean free.
The records also distinguish when the initial charge occurs. Pallas's product and deposit language differ; Luvo's product and refund pages give different signals about charging at intake. See the Pallas review and Luvo review for those exact source conflicts.
Are NAD+ injections worth the cost?
The evidence does not support turning price into an effectiveness score. The NAD+ human pilot examined a short IV infusion and metabolite changes, not whether an at-home subscription improves long-term health. Grant et al.: human NAD+ IV pilot (2019)
Decide with a clinician what outcome would justify treatment and how it would be assessed. The site can make the financial terms clearer, but cannot decide that the benefit is worth the cost for you.
These are products marketed in the longevity category, not established lifespan-extension treatments. Compounded drugs are not FDA-approved. This publication compares public information; a clinician must assess individual suitability. How we compare.